A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

NCT01942083 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: OPB-111077

Sponsor

Korea Otsuka Pharmaceutical Co., Ltd.